Orchid Pharma will license and supply Exblifep to Pharmasyntez JSC to treat complex infections, with Pharmasyntez granted exclusive rights to register and commercialize the drug in Russia and Orchid supplying the finished dosage form.

The agreement targets hospital-acquired bacterial pneumonia and complicated urinary tract infections, leveraging Pharmasyntez’s Russian hospital procurement network.

Financial considerations include how the deal affects debt levels and profit margins, the royalty structure, supply volumes, and managing production costs amid material and supply-chain fluctuations.

The licensing and supply deal boosted Orchid Pharma’s stock, rising about 9% in trading after the announcement.

Investors will watch for how the agreement translates into future revenue growth, export margins, and the regulatory and commercial launch process in Russia.

Post-deal market focus will be on international sales trends, cash flow, and production costs amid evolving global antibiotic pricing.

Readers should independently verify information as details may be updated.

Orchid Pharma, a vertically integrated Indian producer of complex injectable antibiotics, reported Q4 FY2026 net profit of Rs 23.78 crore on revenue of Rs 237.61 crore.

The deal is projected to unlock roughly USD 178 million in potential market opportunities in Russia over the first decade, driven by hospital procurement volumes.

Orchid’s management views the partnership as a strategic step to expand patient access in Russia and broaden its shift from pure antibiotic manufacturing to wider drug discovery and innovation.

Exblifep is FDA and EMA approved and is recognized in IDSA and EUCAST guidelines as the first Indian pharma new chemical entity to receive approvals in both the US and EU.

Pharmasyntez emphasizes addressing antimicrobial resistance and improving access to newer antibacterials like Exblifep for Russian patients.